# 2026年1月12日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 肿瘤微环境塑造胶质母细胞瘤细胞状态的空间组织。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41520155)
**期刊：** Neuro-oncology
**PMID：** 41520155
**DOI：** 10.1093/neuonc/noag003

### 第一部分 原文与翻译

**英文原标题：** Tumor Microenvironment Shapes the Spatial Organization of Glioblastoma Cell States.

> **英文摘要：**
> Glioblastoma is characterized by heterogeneous and plastic cellular populations that adopt transcriptional programs shaped by genetic alterations and microenvironmental cues. Recent studies have identified at least four partially inconvertible cell states-astrocytic-like, neural progenitor-like, oligodendrocyte progenitor-like, and mesenchymal-like-that represent aberrant developmental programs. Expanded analysis further reveals hybrid and intermediate states that form continuous transcriptional and metabolic gradients. These states exhibit spatial organization, assembling into three distinct microanatomical niches: a perivascular niche enriched with mesenchymal-like and oligodendrocyte progenitor-like cells, a hypoxic niche harboring quiescent and stressed cells of all states, and an invasive niche containing astrocyte-like or proneural populations. Niches continuously remodel as cell states transition, migrate, and re-establish new programming in response to angiogenesis, hypoxia, immune infiltration, and neuronal activity. This interplay between states and the microenvironment generates a self-renewing spatial architecture, maintaining expansion at the edge and protection within the core. This review integrates single-cell, single-nucleus, and spatial studies to describe a microenvironmental-driven model of cell state organization. Understanding how these multiscale drives converge to generate a continuum of cell state identities may reveal strategies to disrupt the spatial architecture underlying glioblastoma plasticity and recurrence.

> **中文摘要：**
> 胶质母细胞瘤的特征是具有异质性和可塑性的细胞群体，这些细胞采用由遗传改变和微环境信号塑造的转录程序。最近的研究已鉴定出至少四种部分不可逆的细胞状态——星形胶质细胞样、神经祖细胞样、少突胶质细胞祖细胞样和间充质样——它们代表了异常的发育程序。扩展分析进一步揭示了形成连续转录和代谢梯度的混合及中间状态。这些状态表现出空间组织性，组装成三个不同的微解剖生态位：富含间充质样和少突胶质细胞祖细胞样细胞的血管周生态位、包含所有状态静息和应激细胞的缺氧生态位，以及包含星形胶质细胞样或前神经群落的侵袭生态位。随着细胞状态响应血管生成、缺氧、免疫浸润和神经元活动而发生转变、迁移和重新建立新程序，这些生态位持续重塑。状态与微环境之间的这种相互作用产生了一种自我更新的空间结构，维持了边缘的扩张和核心的保护。本综述整合了单细胞、单核和空间研究，描述了一种微环境驱动的细胞状态组织模型。理解这些多尺度的驱动因素如何汇聚以产生连续的细胞状态身份，可能揭示破坏胶质母细胞瘤可塑性和复发基础的空间结构的策略。

### 第二部分 AI 大师评价

本文综述旨在整合单细胞、单核及空间组学数据，构建一个由微环境驱动的胶质母细胞瘤细胞状态空间组织模型。其核心发现是，异质且可塑的细胞状态在微环境信号（如缺氧、血管生成）驱动下，形成连续的转录-代谢梯度，并空间组装成三个功能特化的解剖生态位，这种动态结构支撑了肿瘤的侵袭扩张与核心保护。该模型的创新性在于从空间维度将细胞状态可塑性与微生态位动态耦合，为理解肿瘤异质性和复发提供了新框架；局限性在于作为综述，其提出的模型仍需更多实验验证，且对驱动这种空间组织的具体分子机制阐述尚不充分。

---

## 2. SMARCAL1是ATRX缺陷型、采用端粒替代延长机制的胶质瘤中一个可靶向的合成致死治疗弱点。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41520142)
**期刊：** Neuro-oncology
**PMID：** 41520142
**DOI：** 10.1093/neuonc/noaf300

### 第一部分 原文与翻译

**英文原标题：** SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use Alternative Lengthening of Telomeres.

> **英文摘要：**
> BACKGROUND: Approximately 10% of cancers achieve replicative immortality through a telomerase-independent mechanism of telomere maintenance, termed Alternative Lengthening of Telomeres (ALT). ALT is particularly prevalent in certain subtypes of malignant gliomas, such as IDH-mutant astrocytoma and pediatric glioblastoma, and frequently co-occurs with ATRX inactivating mutations. Although ALT is an adaptive mechanism through which cancer cells achieve proliferative immortality, the elevated levels of replication stress observed in ALT tumors constitute a potential therapeutic vulnerability.
> 
> METHODS: Leveraging CRISPR/Cas9 screening data from the Cancer Dependency Mapping Project, coupled with patient-derived cell lines and xenografts, we identified SMARCAL1 as a novel synthetic lethal vulnerability in ATRX-deficient glioma models that engage ALT. Using complementary molecular assays for DNA damage, telomere maintenance, and telomeric replication stress, we define the mechanisms underlying cytotoxicity induced by SMARCAL1 depletion in ALT-positive glioma cells.
> 
> RESULTS: Our data demonstrate the annealing helicase SMARCAL1 is a highly specific synthetical lethal vulnerability in cancers that use ALT. SMARCAL1 localizes to ALT-associated PML bodies in ALT-positive glioma cell lines, including IDH-mutant astrocytomas. SMARCAL1 depletion, via doxycycline-induced RNAi, led to a hyperactivation of the ALT phenotype, high levels of DNA double-strand breaks in G2 phase, and cell death via mitotic catastrophe. In mice bearing intracranial xenografts derived from high-grade IDH-mutant astrocytoma, inducible SMARCAL1 depletion prolonged animal survival.
> 
> CONCLUSIONS: Our findings demonstrate that the molecular processes orchestrating ALT-mediated telomere maintenance constitute a targetable synthetic lethal vulnerability that can be exploited by SMARCAL1 inhibition, thus supporting the future development of small molecule inhibitors of SMARCAL1 as anti-cancer therapeutics.

> **中文摘要：**
> 背景：大约10%的癌症通过一种不依赖端粒酶的端粒维持机制实现复制永生，该机制称为端粒替代延长。端粒替代延长在某些恶性胶质瘤亚型中尤为普遍，例如IDH突变型星形细胞瘤和儿童胶质母细胞瘤，并且常与ATRX失活突变共存。尽管端粒替代延长是癌细胞实现增殖永生的适应性机制，但在端粒替代延长肿瘤中观察到的高水平复制应激构成了潜在的治疗弱点。
> 
> 方法：利用来自癌症依赖性图谱项目的CRISPR/Cas9筛选数据，并结合患者来源的细胞系和异种移植模型，我们确定SMARCAL1是参与端粒替代延长的ATRX缺陷型胶质瘤模型中的一个新型合成致死弱点。通过使用针对DNA损伤、端粒维持和端粒复制应激的互补分子检测方法，我们明确了在端粒替代延长阳性胶质瘤细胞中，SMARCAL1耗竭诱导细胞毒性的潜在机制。
> 
> 结果：我们的数据证明，退火解旋酶SMARCAL1是采用端粒替代延长的癌症中一个高度特异性的合成致死弱点。SMARCAL1定位于端粒替代延长阳性胶质瘤细胞系（包括IDH突变型星形细胞瘤）中与端粒替代延长相关的PML小体。通过多西环素诱导的RNAi耗竭SMARCAL1，导致端粒替代延长表型过度激活、G2期高水平DNA双链断裂以及通过有丝分裂灾难导致的细胞死亡。在携带源自高级别IDH突变型星形细胞瘤的颅内异种移植瘤的小鼠中，诱导性SMARCAL1耗竭延长了动物的生存期。
> 
> 结论：我们的研究结果表明，协调端粒替代延长介导的端粒维持的分子过程构成了一个可靶向的合成致死弱点，可通过抑制SMARCAL1加以利用，从而支持未来开发SMARCAL1小分子抑制剂作为抗癌疗法。

### 第二部分 AI 大师评价

本研究旨在探索ATRX缺陷型胶质瘤中端粒替代延长机制的治疗弱点。研究者通过整合CRISPR/Cas9筛选数据与患者来源的模型，结合分子生物学实验，发现SMARCAL1是此类肿瘤的特异性合成致死靶点。其创新性在于首次将SMARCAL1与端粒替代延长表型过度激活及细胞死亡机制明确关联，并在体内模型中验证了靶向该蛋白的治疗潜力，为开发新型抗癌药物提供了直接依据。局限性在于研究主要基于临床前模型，其向临床转化的有效性和安全性尚需进一步验证。

---

## 3. 多组学分析揭示三阴性乳腺癌小鼠模型中具有不同化疗-免疫治疗敏感性的免疫-分子亚群。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41520125)
**期刊：** Molecular cancer
**PMID：** 41520125
**DOI：** 10.1186/s12943-025-02547-9

### 第一部分 原文与翻译

**英文原标题：** Multi-omics profiling uncovers immune-molecular clusters with distinct chemo-immunotherapeutic vulnerabilities in a mouse model of triple-negative breast cancer.

> **英文摘要：**
> BACKGROUND: Triple-negative breast cancer (TNBC) is a highly aggressive and heterogeneous breast cancer subtype with limited treatment options. Predicting patient response to chemo-immunotherapy remains challenging, highlighting the need for robust stratification strategies. METHODS: We performed a multi-parametric analysis combining histological, genomic, transcriptomic, proteomic, and immune profiling in the immunocompetent MMTV-R26 TNBC mouse model and compared outcomes with patient data from human TNBC cohorts and TNBC tumor microarray. To enable therapeutic testing and functional validation, we established syngeneic grafts from primary tumors and used them to evaluate combined chemotherapy (epirubicin) and anti-PD-1 immunotherapy. RESULTS: Multi-parametric analysis of TNBC heterogeneity modeled by the MMTV-R26 mice identified four distinct TNBC clusters, defined by unique intrinsic (molecular/genomic) and extrinsic (immune) features, which closely parallel patient subtypes, including rare metaplastic forms, and correlate with clinical outcomes. Both intrinsic and immune hallmarks of primary tumors were conserved across serial syngeneic transplantations, confirming the translational价值 of this preclinical platform. Treatment assessments indicated cluster-specific therapeutic vulnerabilities associated with molecular and immune traits. Specifically, whereas chemo-immunotherapy is beneficial to neutrophil-enriched tumors, immunotherapy alone appears to be more effective in macrophage-enriched tumors. Our findings indicate that TNBC treatment response is shaped by the interplay between tumor-intrinsic and immune features. CONCLUSION: Our study provides a robust preclinical platform for precision immuno-oncology, enabling stratification of TNBC patients for tailored onco-immunotherapies.

> **中文摘要：**
> 背景：三阴性乳腺癌（TNBC）是一种高度侵袭性且异质性的乳腺癌亚型，治疗选择有限。预测患者对化疗-免疫治疗的反应仍然具有挑战性，这凸显了对稳健分层策略的需求。方法：我们在免疫健全的MMTV-R26 TNBC小鼠模型中进行了结合组织学、基因组学、转录组学、蛋白质组学和免疫特征的多参数分析，并将结果与来自人类TNBC队列和TNBC肿瘤微阵列的患者数据进行比较。为了进行疗效测试和功能验证，我们从原发肿瘤建立了同源移植瘤，并用其评估联合化疗（表柔比星）和抗PD-1免疫治疗。结果：通过对MMTV-R26小鼠模拟的TNBC异质性进行多参数分析，我们鉴定出四个不同的TNBC亚群，这些亚群由独特的内在（分子/基因组）和外在（免疫）特征所定义，它们与患者亚型（包括罕见的化生型）高度平行，并与临床结局相关。原发肿瘤的内在和免疫特征在连续的同源移植过程中均得到保留，证实了该临床前平台的转化价值。治疗评估揭示了与分子和免疫特征相关的亚群特异性治疗敏感性。具体而言，化疗-免疫治疗对中性粒细胞富集的肿瘤有益，而单独的免疫治疗似乎对巨噬细胞富集的肿瘤更有效。我们的研究结果表明，TNBC的治疗反应是由肿瘤内在特征与免疫特征之间的相互作用所塑造的。结论：我们的研究为精准免疫肿瘤学提供了一个稳健的临床前平台，能够对TNBC患者进行分层以实现个体化的肿瘤免疫治疗。

### 第二部分 AI 大师评价

本研究旨在解决TNBC异质性带来的治疗挑战，通过构建免疫健全小鼠模型并进行多组学整合分析，成功模拟并定义了与患者亚型高度对应的免疫-分子亚群。其核心创新在于建立了一个可稳定传代、保留原发瘤特征的临床前平台，并首次在该模型中系统揭示了不同亚群对化疗-免疫联合方案的差异化敏感性，例如中性粒细胞富集与巨噬细胞富集肿瘤的应答模式不同。这为TNBC的精准分型与治疗选择提供了重要的机制见解和转化工具，但结论主要基于小鼠模型，其临床预测效力和普适性仍需在更大规模的患者队列中进行前瞻性验证。

---

## 4. 转录因子HHEX维持糖皮质激素水平并保护肾上腺免受雄激素诱导的脂质耗竭。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41519914)
**期刊：** Nature communications
**PMID：** 41519914
**DOI：** 10.1038/s41467-025-68257-4

### 第一部分 原文与翻译

**英文原标题：** The transcription factor HHEX maintains glucocorticoid levels and protects adrenals from androgen-induced lipid depletion.

> **英文摘要：**
> Glucocorticoid-producing cells of the adrenal cortex (i.e. zona fasciculata, zF) constitute the critical effectors of the hypothalamic-pituitary-adrenal axis, mediating the mammalian stress response. With glucocorticoids being essential for life, zF dysfunction perturbs multiple organs that participate in optimizing cardiometabolic fitness. The zF forms a dynamic and heterogenous cell population endowed with the capacity to remodel through the engagement of both proliferative and differentiation programs that enable the adrenal to adapt and respond to diverse stressors. However, the mechanisms that sustain such differential responsiveness remain poorly understood. In this study, we resolve the transcriptome of the steroidogenic lineage by scRNA-seq using Sf1-Cre; Rosa reporter mice. We identify HHEX, a homeodomain protein, as the most enriched transcription factor in glucocorticoid-producing cells. We utilize genetic mouse models to demonstrate that Hhex deletion causes glucocorticoid deficiency in male animals. Molecularly, we demonstrate that HHEX is an androgen receptor (AR) target gene, shaping the sexual dimorphism of the adrenal gland by repressing the female transcriptional program at puberty, while also maintaining zF cholesterol ester content by protecting lipid droplets from androgen-induced-lipophagy. Moreover, our study reveals that, in both sexes, HHEX is crucial for maintaining the identity of the innermost adrenocortical cell subpopulation. Specifically, loss of HHEX impairs the expression of Abcb1b (P-glycoprotein/MDR1), an efflux pump regulating steroid export and cellular levels of xenobiotics. Together, these data demonstrate that HHEX serves as a multi-functional regulator of post-natal adrenal maturation that is potentiated by androgens.

> **中文摘要：**
> 肾上腺皮质中产生糖皮质激素的细胞（即束状带，zF）是下丘脑-垂体-肾上腺轴的关键效应器，介导哺乳动物的应激反应。糖皮质激素对生命至关重要，zF功能障碍会扰乱参与优化心脏代谢健康的多个器官。zF形成了一个动态且异质性的细胞群体，具有通过启动增殖和分化程序进行重塑的能力，从而使肾上腺能够适应并响应各种应激源。然而，维持这种差异性反应能力的机制仍知之甚少。在本研究中，我们利用Sf1-Cre; Rosa报告小鼠，通过单细胞RNA测序解析了类固醇生成谱系的转录组。我们鉴定出同源域蛋白HHEX是糖皮质激素生成细胞中最富集的转录因子。我们利用遗传小鼠模型证明，Hhex缺失会导致雄性动物糖皮质激素缺乏。在分子层面，我们证明HHEX是雄激素受体（AR）的靶基因，通过在青春期抑制雌性转录程序来塑造肾上腺的性别二态性，同时通过保护脂滴免受雄激素诱导的脂噬作用来维持zF胆固醇酯含量。此外，我们的研究揭示，在两种性别中，HHEX对于维持最内层肾上腺皮质细胞亚群的特性都至关重要。具体而言，HHEX缺失会损害Abcb1b（P-糖蛋白/MDR1）的表达，这是一种调节类固醇输出和异生物质细胞水平的外排泵。总之，这些数据表明，HHEX是出生后肾上腺成熟的多功能调节因子，其功能受雄激素增强。

### 第二部分 AI 大师评价

本研究旨在探究维持肾上腺皮质束状带（zF）细胞功能异质性与应激适应性的分子机制。研究团队运用单细胞RNA测序结合遗传小鼠模型，首次将转录因子HHEX鉴定为糖皮质激素生成细胞的关键富集因子，并系统阐明了其在肾上腺稳态中的多重功能。核心发现揭示了HHEX作为雄激素受体靶基因，在塑造肾上腺性别二态性、维持脂质储备以及调控最内层皮质细胞特性方面发挥不可或缺的作用，其机制涉及对“雌性程序”的抑制、对脂噬的保护以及对外排泵Abcb1b的调控。该研究的创新性在于将HHEX确立为连接雄激素信号、脂质代谢与细胞身份维持的核心枢纽，为理解肾上腺的性别差异及应激适应提供了全新视角；局限性在于主要基于小鼠模型，其结论在人类肾上腺中的普适性有待进一步验证，且HHEX下游的具体效应网络仍需深入解析。

---

## 5. 单细胞多重方法深度绘制CRISPR靶向基因毒性图谱，并揭示帕博西尼与长期植入对其的缓解作用。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41519897)
**期刊：** Nature communications
**PMID：** 41519897
**DOI：** 10.1038/s41467-025-68177-3

### 第一部分 原文与翻译

**英文原标题：** Single-cell multiplex approaches deeply map ON-target CRISPR-genotoxicity and reveal its mitigation by palbociclib and long-term engraftment.

> **英文摘要：**
> Genome editing by CRISPR-Cas9-nuclease is promising for gene therapy. However, safety concerns remain. Monitoring ON-target genotoxicity is essential, especially to assay megabasic rearrangements at the targeted locus. Here, we developed a combined single-cell resolution approach with DNA sequencing focused on single nucleotide polymorphism (scSNP-DNAseq), micronuclei and LOH cytometry-reporter assays. This sensitive multiplexed strategy enables the sensitive monitoring of CRISPR-mediated genotoxicity in primary cells. Using this approach, we detect, map and characterize various types of induced-losses of heterozygosity and assess editing-associated chromosomal instability. Importantly, palbociclib prevents the appearance of such genomic rearrangements in hematopoietic stem cells without impairing cell命运 or graft capability. Conversely, short-term risk is significantly increased with DNA-PKcs inhibitor AZD7648. Fortunately, targeting HBG1/2p, scSNP-DNA-seq reveals that ON-target genotoxic events are no longer detectable after long-term xenografts. This work demonstrates that scSNP-DNA-seq should be routinely implemented to monitor chromosomal rearrangements before and after CRISPR-edited cell infusions.

> **中文摘要：**
> CRISPR-Cas9核酸酶介导的基因组编辑在基因治疗中前景广阔。然而，安全性问题依然存在。监测靶向基因毒性至关重要，特别是检测靶位点的大片段重排。在此，我们开发了一种结合单细胞分辨率的方法，包括聚焦于单核苷酸多态性的DNA测序（scSNP-DNAseq）、微核以及杂合性缺失流式细胞报告实验。这种灵敏的多重策略能够实现对原代细胞中CRISPR介导的基因毒性的灵敏监测。利用该方法，我们检测、绘制并表征了多种类型的诱导性杂合性缺失，并评估了与编辑相关的染色体不稳定性。重要的是，帕博西尼能够阻止造血干细胞中出现此类基因组重排，且不影响细胞命运或移植能力。相反，DNA-PKcs抑制剂AZD7648会显著增加短期风险。幸运的是，针对HBG1/2p位点，scSNP-DNA-seq显示，在长期异种移植后，靶向基因毒性事件不再能被检测到。这项工作表明，应在CRISPR编辑细胞输注前后常规实施scSNP-DNA-seq以监测染色体重排。

### 第二部分 AI 大师评价

本研究旨在解决CRISPR-Cas9基因治疗中关键的靶向基因毒性安全问题。其核心创新在于开发并整合了scSNP-DNAseq、微核及LOH报告系统等多重单细胞技术，构建了一个高灵敏度的监测平台，能够深度绘制和表征编辑诱导的染色体异常。研究发现，细胞周期抑制剂帕博西尼可有效预防重排，而DNA-PK抑制剂则增加风险，这为优化编辑方案提供了重要线索；同时，长期移植后毒性事件消失的观察结果，为CRISPR疗法的长期安全性提供了积极证据。然而，研究主要聚焦于造血干细胞和特定靶点（HBG1/2p），其结论在其他细胞类型和基因组位点的普适性仍需进一步验证。

---

## 6. SHOC2-KRAS-PP1C复合物的结构揭示了RAS亚型特异性决定因素，并为RAS抑制剂靶向复合物组装提供了见解。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41519889)
**期刊：** Nature communications
**PMID：** 41519889
**DOI：** 10.1038/s41467-026-68319-1

### 第一部分 原文与翻译

**英文原标题：** Structure of SHOC2-KRAS-PP1C complex reveals RAS isoform-specific determinants and insights into targeting complex assembly by RAS inhibitors.

> **英文摘要：**
> RAF activation is essential for MAPK signaling and is mediated by RAS binding and the dephosphorylation of a conserved phosphoserine by the SHOC2-RAS-PP1C complex. MRAS forms a high-affinity SHOC2-MRAS-PP1C (SMP) complex, while canonical RAS isoforms (KRAS, HRAS, NRAS) form analogous but lower-affinity assemblies. Yet, cancers driven by oncogenic KRAS, HRAS, or NRAS remain strongly SHOC2-dependent, suggesting that these weaker complexes contribute to tumorigenesis. To elucidate how canonical RAS proteins form lower-affinity ternary complexes, the cryo-EM structure of the SHOC2-KRAS-PP1C (SKP) complex stabilized by Noonan syndrome mutations is described. The SKP architecture is similar to the SMP complex but forms fewer contacts and buries less surface area due to the absence of MRAS-specific structural features in KRAS that enhance complex stability. RAS inhibitors MRTX1133 and RMC-6236 alter Switch-I/II conformations, thereby blocking SKP assembly more effectively than they disrupt preformed complexes. These RAS inhibitors do not affect SMP formation because they do not bind MRAS. Since MRAS is upregulated in resistance to KRAS inhibition, we characterize a MRAS mutant capable of binding MRTX1133. This MRAS mutant can form an SMP complex, but MRTX1133 blocks its assembly, demonstrating the feasibility of dual SKP and SMP targeting. Overall, our findings define isoform-specific differences in SHOC2-RAS-PP1C complex formation and support a strategy to prevent both SKP and SMP assemblies to overcome resistance in RAS-driven cancers.

> **中文摘要：**
> RAF激活对于MAPK信号传导至关重要，它由RAS结合以及SHOC2-RAS-PP1C复合物对保守磷酸丝氨酸的去磷酸化所介导。MRAS形成高亲和力的SHOC2-MRAS-PP1C（SMP）复合物，而经典的RAS亚型（KRAS、HRAS、NRAS）则形成类似但亲和力较低的组装体。然而，由致癌性KRAS、HRAS或NRAS驱动的癌症仍然强烈依赖SHOC2，这表明这些较弱的复合物促进了肿瘤发生。为了阐明经典RAS蛋白如何形成低亲和力三元复合物，本文描述了由Noonan综合征突变稳定的SHOC2-KRAS-PP1C（SKP）复合物的冷冻电镜结构。SKP的结构与SMP复合物相似，但由于KRAS缺乏MRAS特有的、能增强复合物稳定性的结构特征，其形成的相互作用更少，埋藏的表面积也更小。RAS抑制剂MRTX1133和RMC-6236改变了Switch-I/II的构象，从而比破坏已形成的复合物更有效地阻止SKP的组装。这些RAS抑制剂不影响SMP的形成，因为它们不结合MRAS。鉴于MRAS在KRAS抑制耐药中表达上调，我们表征了一个能够结合MRTX1133的MRAS突变体。该MRAS突变体可以形成SMP复合物，但MRTX1133能阻断其组装，这证明了同时靶向SKP和SMP的可行性。总之，我们的研究结果明确了SHOC2-RAS-PP1C复合物形成中的亚型特异性差异，并支持一种通过同时阻止SKP和SMP组装来克服RAS驱动癌症耐药性的策略。

### 第二部分 AI 大师评价

本研究旨在解析经典RAS亚型（如KRAS）与SHOC2、PP1C形成低亲和力复合物（SKP）的结构基础，并探索RAS抑制剂对复合物组装的干预机制。研究团队通过冷冻电镜解析了由Noonan综合征突变稳定的SKP复合物结构，并与高亲和力的MRAS复合物（SMP）进行对比，揭示了MRAS特异性结构特征对稳定性的关键作用。创新性地发现，RAS抑制剂通过改变Switch区构象来更有效地阻止SKP组装，而非破坏已形成的复合物，并进一步通过工程化MRAS突变体，验证了同时靶向SKP和SMP以克服耐药性的可行性，为RAS驱动癌症的治疗提供了新策略。然而，研究主要基于结构分析和体外实验，其在体内肿瘤模型和临床转化中的有效性仍需进一步验证。

---

## 7. Rad51决定复制后修复中的通路选择。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41519855)
**期刊：** Nature communications
**PMID：** 41519855
**DOI：** 10.1038/s41467-025-68109-1

### 第一部分 原文与翻译

**英文原标题：** Rad51 determines pathway usage in post-replication repair.

> **英文摘要：**
> Stalled replication forks are processed in post-replication repair by homologous recombination, fork regression, and translesion DNA synthesis. However, the regulation of pathway usage is not fully understood. Rad51 protein maintains genomic stability through its roles in recombination and in protecting stalled replication forks. We report isolation of mutations in Saccharomyces cerevisiae Rad51 that shift post-replication repair from recombination to alternate pathways including mutagenic translesion synthesis. Rad51-E135D and Rad51-K305N show near normal in vitro recombination despite changes in their DNA binding profiles, in particular to dsDNA. The mutants lead to a defect in Rad51 recruitment to stalled forks in vivo as well as a defect in the protection of dsDNA from degradation by Dna2-Sgs1 and Exo1 in vitro. Together, the evidence suggests that Rad51 binding to duplex DNA is critical to control pathway usage at stalled replication forks.

> **中文摘要：**
> 停滞的复制叉在复制后修复中通过同源重组、复制叉回归和跨损伤DNA合成等方式进行处理。然而，通路选择的调控机制尚未完全阐明。Rad51蛋白通过其在重组和保护停滞复制叉中的作用来维持基因组稳定性。我们报道了在酿酒酵母Rad51中分离出的突变，这些突变使复制后修复从重组转向包括诱变性跨损伤合成在内的替代通路。Rad51-E135D和Rad51-K305N突变体尽管其DNA结合谱（特别是对双链DNA的结合）发生了变化，但在体外仍显示出接近正常的重组活性。这些突变体导致体内Rad51向停滞复制叉的募集存在缺陷，并且在体外也表现出无法保护双链DNA免受Dna2-Sgs1和Exo1降解的缺陷。总之，这些证据表明，Rad51与双链DNA的结合对于控制停滞复制叉处的通路选择至关重要。

### 第二部分 AI 大师评价

本研究旨在阐明Rad51蛋白如何调控复制后修复（PRR）中的通路选择。研究团队通过分离并表征酿酒酵母Rad51的特定点突变（E135D和K305N），巧妙地揭示了Rad51在DNA损伤位点的功能分工：其与双链DNA（dsDNA）的结合能力，而非其经典的重组催化活性，是决定PRR偏向于同源重组还是诱变性跨损伤合成（TLS）的关键。这一发现创新性地将Rad51的DNA结合特性与其在复制叉保护和非重组通路抑制中的功能直接联系起来，深化了对基因组稳定性维护机制的理解。然而，研究主要基于酵母模型和体外实验，其在高等真核生物中的普适性以及Rad51-dsDNA结合如何精确影响下游效应蛋白的分子细节，仍有待进一步探索。

---

## 8. 花生四烯酸通过线粒体自噬的非自噬功能诱导细胞焦亡并增强PDAC模型中的免疫治疗效果。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41519804)
**期刊：** Nature communications
**PMID：** 41519804
**DOI：** 10.1038/s41467-025-68267-2

### 第一部分 原文与翻译

**英文原标题：** Arachidonic acid induces pyroptosis via a non-autophagic function of mitophagy and enhances immunotherapy in a PDAC model.

> **英文摘要：**
> Pancreatic ductal adenocarcinoma (PDAC) presents a therapeutic hurdle owing to its immunotherapy resistance and limited treatment options. Pyroptosis, a lytic inflammatory cell death pathway, holds promise for reversing immunosuppression in "cold" tumors, yet tumor-specific induction strategies remain unclear. Here, we employ a contrastive learning graph neural network to identify arachidonic acid (AA), an endogenous ω-6 polyunsaturated fatty acid, as a pan-cancer pyroptosis inducer operating through irreversible mitochondrial permeability transition inducing Caspase 3/GSDME activation. Crucially, a repurposed mitophagy machinery for non-autophagic functional scaffolding of Caspase 3/GSDME on autophagosomal membranes enables rapid pyroptotic execution. Pharmacological accumulation of autophagosomes amplifies AA-induced pyroptosis in PDAC organoids and patient-derived xenografts. Furthermore, AA-triggered pyroptosis, remodels immunosuppressive tumor microenvironments, boosting cytotoxic T cell infiltration and synergizing with anti-PD-1 therapy in immunocompetent models. Thus, our findings position AA as a candidate dual-function agent for pyroptosis-immune synergy, while autophagosome manipulation emerges as a strategy to potentiating strategy.

> **中文摘要：**
> 胰腺导管腺癌（PDAC）因其对免疫治疗的抵抗性和有限的治疗选择而构成治疗障碍。细胞焦亡是一种裂解性炎症细胞死亡途径，有望逆转“冷”肿瘤的免疫抑制，但肿瘤特异性诱导策略仍不明确。在此，我们采用对比学习图神经网络，鉴定出内源性ω-6多不饱和脂肪酸花生四烯酸（AA）是一种通过不可逆的线粒体通透性转换诱导Caspase 3/GSDME激活的泛癌焦亡诱导剂。关键的是，一个被重新利用的线粒体自噬机制，在自噬体膜上为Caspase 3/GSDME提供非自噬性的功能支架，从而实现了快速的焦亡执行。药物性积累自噬体可放大AA在PDAC类器官和患者来源异种移植模型中诱导的焦亡。此外，AA触发的焦亡重塑了免疫抑制性肿瘤微环境，促进了细胞毒性T细胞浸润，并在免疫健全模型中与抗PD-1疗法产生协同作用。因此，我们的研究结果将AA定位为一种具有焦亡-免疫协同作用的候选双功能剂，而自噬体操控则成为一种增强策略的潜在方法。

### 第二部分 AI 大师评价

本研究旨在探索克服胰腺癌免疫治疗抵抗的新策略。核心方法是利用AI模型（对比学习图神经网络）筛选出花生四烯酸（AA）作为焦亡诱导剂，并揭示了其通过线粒体自噬机制的非经典“支架”功能激活Caspase 3/GSDME通路的独特机制。主要发现是AA不仅能特异性诱导肿瘤细胞焦亡，还能重塑免疫微环境，与抗PD-1疗法产生协同效应，为“冷”肿瘤的免疫增敏提供了新思路。其创新性在于将代谢物、细胞死亡与自噬过程交叉关联，并提出了自噬体积累这一可药用的增效策略；局限性在于目前结论主要基于临床前模型，其人体内的安全性与有效性有待验证。

---

## 9. 肿瘤相关巨噬细胞通过激活NOTCH2-JAG1近分泌信号通路促进紫杉醇耐药。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41519773)
**期刊：** Molecular cancer
**PMID：** 41519773
**DOI：** 10.1186/s12943-025-02546-w

### 第一部分 原文与翻译

**英文原标题：** Tumor-associated macrophages promote chemoresistance to Paclitaxel via activating NOTCH2-JAG1 juxtacrine signaling.

> **英文摘要：**
> BACKGROUND: Taxane-based chemotherapy is a main treatment modality for ovarian cancer and other solid tumors, but chemoresistance limits the clinical efficacy. Studies have shown tumor interaction with macrophages in the tumor microenvironment (TME) plays a significant role in taxane resistance, yet the underlying molecular mechanisms are poorly understood.
> 
> METHODS: In this study, we employed translatome profiling of paclitaxel-treated cancer cells, live-cell imaging analysis, gene knockdown/knockout, and in vitro cancer-macrophage coculture assays to unravel a novel chemoresistance mechanism mediated by tumor-macrophage interaction via the NOTCH2-JAG1 axis. The in vitro data were further validated by multiple xenograft, syngeneic and patient-derived xenograft mouse tumor models of ovarian cancer as well as ovarian cancer patient samples.
> 
> RESULTS: We found paclitaxel selectively induced translational upregulation of NOTCH2 via cytoplasmic polyadenylation, and this NOTCH2 upregulation persisted after mitotic exit. Subsequent NOTCH2 activation by JAG1 expressed mainly on the neighboring macrophages promoted tumor细胞存活并模拟细胞因子释放，例如CSF1和IL-1β，这些细胞因子招募表达JAG1的巨噬细胞，从而形成一个正反馈环路，进一步增强了促肿瘤的NOTCH2活性。在多种卵巢癌临床前模型中，通过基因敲除或使用γ-分泌酶抑制剂进行药理学抑制来阻断NOTCH2，可减弱巨噬细胞浸润并使肿瘤对紫杉醇的反应增敏。此外，单细胞RNA测序分析鉴定出一个JAG1高表达的巨噬细胞亚群，该亚群在紫杉醇治疗后富集，并可被NOTCH抑制所减弱。在临床上，卵巢肿瘤中NOTCH2的高表达与卵巢癌患者的复发和较短的无进展生存期相关。
> 
> CONCLUSIONS: Paclitaxel-induced translational upregulation of NOTCH2 enables immediate juxtacrine activation by JAG1-positive macrophages, coupling tumor cell survival with immune remodeling in the tumor microenvironment to drive chemoresistance. Our results suggest NOTCH2 is a viable biomarker for paclitaxel resistance and that combining NOTCH2 inhibitor with taxane is an effective therapeutic strategy to selectively disrupt tumor-macrophage interaction and overcome macrophage-mediated taxane resistance in NOTCH2-positive tumors.

> **中文摘要：**
> 背景：以紫杉烷类药物为基础的化疗是卵巢癌和其他实体瘤的主要治疗方式，但化疗耐药限制了其临床疗效。研究表明，肿瘤与肿瘤微环境（TME）中巨噬细胞的相互作用在紫杉烷耐药中起重要作用，但其潜在的分子机制尚不清楚。
> 
> 方法：在本研究中，我们采用紫杉醇处理的癌细胞的翻译组分析、活细胞成像分析、基因敲低/敲除以及体外肿瘤-巨噬细胞共培养实验，来揭示一种由肿瘤-巨噬细胞通过NOTCH2-JAG1轴相互作用介导的新型化疗耐药机制。体外数据通过多种卵巢癌的异种移植、同源移植和患者来源异种移植小鼠肿瘤模型以及卵巢癌患者样本得到进一步验证。
> 
> 结果：我们发现紫杉醇通过胞质多聚腺苷酸化选择性诱导NOTCH2的翻译上调，并且这种NOTCH2上调在有丝分裂退出后持续存在。随后，主要由邻近巨噬细胞表达的JAG1激活NOTCH2，促进了肿瘤细胞存活并模拟细胞因子（如CSF1和IL-1β）的释放，这些细胞因子招募表达JAG1的巨噬细胞，从而形成一个正反馈环路，进一步增强了促肿瘤的NOTCH2活性。在多种卵巢癌临床前模型中，通过基因敲除或使用γ-分泌酶抑制剂进行药理学抑制来阻断NOTCH2，可减弱巨噬细胞浸润并使肿瘤对紫杉醇的反应增敏。此外，单细胞RNA测序分析鉴定出一个JAG1高表达的巨噬细胞亚群，该亚群在紫杉醇治疗后富集，并可被NOTCH抑制所减弱。在临床上，卵巢肿瘤中NOTCH2的高表达与卵巢癌患者的复发和较短的无进展生存期相关。
> 
> 结论：紫杉醇诱导的NOTCH2翻译上调使得JAG1阳性巨噬细胞能够立即进行近分泌激活，将肿瘤细胞存活与肿瘤微环境中的免疫重塑耦合，从而驱动化疗耐药。我们的结果表明，NOTCH2是紫杉醇耐药的一个可行生物标志物，并且将NOTCH2抑制剂与紫杉烷类药物联合使用是一种有效的治疗策略，可以选择性地破坏肿瘤-巨噬细胞相互作用，并克服NOTCH2阳性肿瘤中巨噬细胞介导的紫杉烷耐药。

### 第二部分 AI 大师评价

本研究旨在揭示肿瘤相关巨噬细胞（TAMs）介导紫杉醇耐药的具体分子机制。通过整合翻译组学、活细胞成像、基因编辑、体外共培养及多种体内模型，研究者系统性地论证了NOTCH2-JAG1近分泌信号轴的核心作用。其核心发现是紫杉醇通过翻译调控选择性上调肿瘤细胞NOTCH2，进而被巨噬细胞JAG1激活，形成一个驱动耐药和免疫重塑的正反馈环路。研究的创新性在于从翻译调控层面解析了耐药启动机制，并提出了NOTCH2作为预测标志物和联合治疗靶点的转化潜力。局限性在于，结论主要基于卵巢癌模型，在其他紫杉烷敏感的实体瘤中的普适性有待验证，且联合治疗策略的临床安全性与有效性需进一步评估。

---

## 10. 重新思考CLDN18.2表达在胃癌治疗中的作用——作者回复

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41519592)
**期刊：** Lancet (London, England)
**PMID：** 41519592
**DOI：** 10.1016/S0140-6736(25)02356-6

### 第一部分 原文与翻译

**英文原标题：** Rethinking CLDN18.2 expression in gastric cancer therapy - Authors' reply.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文是作者对先前关于CLDN18.2靶向治疗讨论的回应，核心目的在于澄清或深化对CLDN18.2表达在胃癌治疗中价值的理解。作为一篇回复性文章，其方法侧重于基于现有证据进行观点阐述与辩论，而非报告新的研究数据。其主要发现或立场可能涉及对CLDN18.2作为生物标志物的解读、患者筛选策略或治疗应答机制的再思考。其创新性在于提供了该领域前沿讨论的直接反馈，但局限性在于缺乏独立的原始数据支持，其结论高度依赖于所回应的原文及已有文献背景。

---

## 11. 重新审视CLDN18.2表达在胃癌治疗中的作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41519591)
**期刊：** Lancet (London, England)
**PMID：** 41519591
**DOI：** 10.1016/S0140-6736(25)02071-9

### 第一部分 原文与翻译

**英文原标题：** Rethinking CLDN18.2 expression in gastric cancer therapy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文标题提示，这是一篇发表于《柳叶刀》的评论或观点文章，旨在重新评估CLDN18.2作为胃癌治疗靶点的临床意义。其核心目的可能是对现有靶向CLDN18.2的治疗策略（如单克隆抗体）进行批判性审视，探讨其在患者选择、疗效预测或耐药机制等方面的局限性或新见解。鉴于无摘要，推测其方法可能基于现有临床数据和生物学证据进行综合分析。其创新性在于可能挑战或深化当前对CLDN18.2生物标志物价值的理解，为优化精准治疗提供新思路。主要局限性在于无法获知其具体论证细节和结论。

---

## 12. PD-1抑制剂作为儿童霍奇金淋巴瘤一线治疗的行动倡议

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41519588)
**期刊：** Lancet (London, England)
**PMID：** 41519588
**DOI：** 10.1016/S0140-6736(25)02386-4

### 第一部分 原文与翻译

**英文原标题：** Action for first-line PD-1 inhibitors in paediatric Hodgkin lymphoma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文标题聚焦于PD-1抑制剂在儿童霍奇金淋巴瘤一线治疗中的应用。鉴于摘要不可用，推测其核心目的可能是探讨将免疫检查点抑制剂前移至儿童患者初始治疗阶段的必要性、理论基础或临床数据。其潜在创新性在于挑战传统化疗模式，为降低远期毒性提供新策略。然而，缺乏摘要信息也意味着无法评估其具体研究方法、关键发现及潜在的局限性，如安全性数据、长期疗效或患者选择标准等。

---

## 13. 质子治疗是否已成为口咽癌的新标准治疗方案？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41519583)
**期刊：** Lancet (London, England)
**PMID：** 41519583
**DOI：** 10.1016/S0140-6736(25)02639-X

### 第一部分 原文与翻译

**英文原标题：** Is proton therapy a new standard of care for oropharyngeal cancer?

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文标题以设问形式，直接指向质子治疗在口咽癌治疗标准中的潜在地位这一核心议题。其核心目的旨在探讨质子治疗相较于传统放疗（如光子放疗）的临床价值与定位。由于摘要不可用，推测其方法可能基于现有临床证据或专家共识进行评述，发现可能涉及质子治疗在靶区适形性、减少正常组织毒性（如吞咽功能保留）等方面的优势。其创新性在于聚焦于前沿放疗技术对特定癌症治疗标准的重塑，但局限性在于缺乏摘要，无法评估其结论所依据的具体证据强度与研究设计。

---

## 14. 美国口咽癌患者的质子与光子放疗对比：一项多中心、随机、开放标签、非劣效性3期试验。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41391462)
**期刊：** Lancet (London, England)
**PMID：** 41391462
**DOI：** 10.1016/S0140-6736(25)01962-2

### 第一部分 原文与翻译

**英文原标题：** Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial.

> **英文摘要：**
> BACKGROUND: Radiotherapy is an integral component of treatment for oropharyngeal cancer. Toxicity from the current state-of-the-art photon radiotherapy, intensity-modulated radiation therapy (IMRT), has prompted the search for alternative, less toxic therapies. One such alternative that might de-intensify treatment is proton therapy. In this trial, we aimed to directly compare IMRT with intensity-modulated proton therapy (IMPT), both concurrent with systemic therapy, hypothesising comparable disease control and survival and lower toxicity.
> 
> METHODS: This randomised, multicentre, open-label, non-inferiority, phase 3 trial was conducted in 21 sites (cancer centres or universities) in the USA. Patients (aged ≥18 years) with stage III or stage IV oropharyngeal cancer and an Eastern Cooperative Oncology Group performance status of 0-2 were recruited and randomly assigned 1:1 to receive IMPT or IMRT. All patients were treated with radiotherapy to 70 Gy in 33 fractions to the primary tumour site and cervical lymphadenopathy. The type, schedule, and dose of induction or concurrent systemic therapy were chosen locally by each institution's multidisciplinary tumour board and were consistent with international guidelines. The primary endpoint was progression-free survival and was assessed in the intention-to-treat population; safety outcomes were assessed in the per-protocol population (ie, patients who received the assigned therapy). A non-inferiority margin of 9 percentage points for progression-free survival at 3 years was used. This trial is registered with ClinicalTrials.gov (NCT01893307) and is closed to further accrual after prespecified interim analysis.
> 
> FINDINGS: From Oct 10, 2013, to May 1, 2022, 440 patients consented (median age 61 years [IQR 55-68], 399 [91%] male, 409 [93%] White); 221 were allocated to the IMPT group (with 160 [72%] receiving IMPT) and 219 to the IMRT group (136 [62%] receiving IMRT). At a median follow-up time of 3·2 years, progression-free survival rates for the IMPT group were 82·5% (95% CI 76·1-87·3) at 3 years and 81·3% (74·5-86·5) at 5 years; corresponding rates for the IMRT group were 83·0% (76·7-87·7) and 76·2% (68·0-82·6; hazard ratio [HR] 0·88 [95% CI 0·57-1·35]; p=0·005 for non-inferiority of IMPT). Overall survival rates after IMPT were 90·9% at 5 years versus 81·0% after IMRT (HR 0·58 [95% CI 0·34-0·99]; p=0·045). Treatment-related deaths occurred in nine patients; six in the IMRT group and three in the IMPT group. Deaths from disease progression occurred in 27 patients; 18 in the IMRT group and nine in the IMPT group. 5-year disease control rates for IMPT versus IMRT were similar between treatment groups (local recurrences 2·9% vs 5·6%, p=0·474; regional recurrences 3·4% vs 3·2%, p=0·860; and distant metastases 9·1% vs 8·9%, p=0·897). Severe lymphopenia was more common in the IMRT group (89% vs 76%), as were dysphagia (49% vs 31%), xerostomia (45% vs 33%), and gastrostomy tube dependence (40·2% vs 26·8%; p=0·018).
> 
> INTERPRETATION: IMPT showed non-inferiority to IMRT for progression-free survival, improvement in overall survival, similar disease control, and reduced high-grade toxicity relative to IMRT. Treatment-related and post-progression deaths occurred more frequently with IMRT. IMPT is a new standard-of-care treatment option for patients with oropharyngeal cancer.
> 
> FUNDING: MD Anderson Cancer Center, Massachusetts General Hospital, National Institutes of Health, Hitachi America.

> **中文摘要：**
> 背景：放射治疗是口咽癌治疗的重要组成部分。当前最先进的光子放疗——调强放射治疗（IMRT）的毒性促使人们寻找替代性的、毒性更低的疗法。质子治疗就是这样一种可能降低治疗强度的替代方案。在本试验中，我们旨在直接比较IMRT与调强质子治疗（IMPT），两者均联合全身治疗，假设其疾病控制和生存率相当且毒性更低。
> 
> 方法：这项随机、多中心、开放标签、非劣效性3期试验在美国的21个中心（癌症中心或大学）进行。招募了III期或IV期口咽癌且美国东部肿瘤协作组体能状态评分为0-2的患者（年龄≥18岁），并按1:1随机分配接受IMPT或IMRT。所有患者均接受放疗，对原发肿瘤部位和颈部淋巴结转移灶给予70 Gy/33次分割的照射。诱导或同步全身治疗的类型、方案和剂量由各机构的多学科肿瘤委员会根据当地情况选择，并符合国际指南。主要终点是无进展生存期，在意向治疗人群中进行评估；安全性结果在符合方案人群（即接受了分配治疗的患者）中进行评估。使用了3年无进展生存率9个百分点的非劣效界值。本试验已在ClinicalTrials.gov注册（NCT01893307），并在预设的中期分析后停止招募。
> 
> 结果：从2013年10月10日到2022年5月1日，共440名患者同意参与（中位年龄61岁[IQR 55-68]，399名[91%]男性，409名[93%]白人）；221名被分配至IMPT组（其中160名[72%]接受了IMPT），219名被分配至IMRT组（136名[62%]接受了IMRT）。中位随访时间为3.2年，IMPT组的3年和5年无进展生存率分别为82.5%（95% CI 76.1-87.3）和81.3%（74.5-86.5）；IMRT组的相应比率分别为83.0%（76.7-87.7）和76.2%（68.0-82.6；风险比[HR] 0.88 [95% CI 0.57-1.35]；IMPT非劣效性检验p=0.005）。IMPT后的5年总生存率为90.9%，而IMRT后为81.0%（HR 0.58 [95% CI 0.34-0.99]；p=0.045）。治疗相关死亡发生在9名患者中；IMRT组6名，IMPT组3名。疾病进展导致的死亡发生在27名患者中；IMRT组18名，IMPT组9名。IMPT与IMRT的5年疾病控制率在各治疗组间相似（局部复发率2.9% vs 5.6%，p=0.474；区域复发率3.4% vs 3.2%，p=0.860；远处转移率9.1% vs 8.9%，p=0.897）。严重淋巴细胞减少在IMRT组更常见（89% vs 76%），吞咽困难（49% vs 31%）、口干症（45% vs 33%）和胃造瘘管依赖（40.2% vs 26.8%；p=0.018）也是如此。
> 
> 解读：IMPT在无进展生存方面显示出对IMRT的非劣效性，总生存期有所改善，疾病控制相似，并且相对于IMRT降低了高级别毒性。治疗相关和进展后死亡在IMRT组发生更频繁。IMPT是口咽癌患者的一种新的标准治疗选择。
> 
> 资助：MD安德森癌症中心、麻省总医院、美国国立卫生研究院、日立美国公司。

### 第二部分 AI 大师评价

本研究是一项关键的3期随机对照试验，直接比较了调强质子治疗（IMPT）与标准调强光子放疗（IMRT）联合全身治疗用于口咽癌的效果。其核心目的是验证IMPT在疗效非劣效的前提下，能否显著降低治疗毒性。研究设计严谨，采用多中心、开放标签、非劣效性设计，主要终点为无进展生存期。研究发现，IMPT不仅达到了非劣效性标准，还显示出总生存获益的趋势，并显著降低了包括严重淋巴细胞减少、吞咽困难、口干症和胃造瘘管依赖在内的高级别毒性事件发生率。该研究为IMPT作为口咽癌新的标准治疗选择提供了高级别循证医学证据，其局限性可能包括开放标签设计潜在的偏倚、随访时间尚不足以评估长期生存差异，以及研究人群以白人和男性为主，可能限制结果的普遍适用性。

---

## 15. Epcoritamab联合来那度胺和利妥昔单抗对比来那度胺和利妥昔单抗治疗复发或难治性滤泡性淋巴瘤（EPCORE FL-1）：一项全球、开放标签、随机、3期试验。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41371238)
**期刊：** Lancet (London, England)
**PMID：** 41371238
**DOI：** 10.1016/S0140-6736(25)02360-8

### 第一部分 原文与翻译

**英文原标题：** Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.

> **英文摘要：**
> BACKGROUND: An unmet need persists for chemotherapy-free regimens that induce durable responses for relapsed or refractory follicular lymphoma. Lenalidomide and rituximab (R) is an accepted standard of care in this population. The EPCORE FL-1 trial aimed to evaluate the efficacy and safety of epcoritamab plus R versus R in participants with relapsed or refractory follicular lymphoma after at least one previous line of chemoimmunotherapy.
> 
> METHODS: In this multicountry, open-label, phase 3 trial, participants were randomly allocated (1:1) to fixed-duration epcoritamab plus R or R for up to 12 cycles. Epcoritamab was administered weekly in cycles 1-3 and every 4 weeks in cycles 4-12, lenalidomide once daily during cycles 1-12 (days 1-21), and rituximab weekly during cycle 1 and monthly in cycles 2-5. The dual primary endpoints were overall response rate and progression-free survival by independent review committee. The data reported here are from a planned interim analysis carried out after 78% of progression-free survival events had occurred. This study is registered with ClinicalTrials.gov, NCT05409066, and EudraCT, 2021-000169-34, and is ongoing (closed to recruitment).
> 
> FINDINGS: Out of 668 participants screened for eligibility across 189 academic and non-academic centres in 30 countries across Africa, Asia, Australia, Europe, North America, and South America, a total of 488 participants were randomly allocated, 243 to epcoritamab plus R and 245 to R. The trial met its dual primary endpoints, showing superiority of epcoritamab plus R over R in overall response rate and progression-free survival. With a median follow-up of 14·8 months (IQR 11·4-19·0), overall response rate was 95% (95% CI 92-97) with epcoritamab plus R versus 79% (74-84; p<0·0001) with R. Progression-free survival was longer with epcoritamab plus R versus R (hazard ratio 0·21 [95% CI 0·14-0·31], p<0·0001); estimated 16-month progression-free survival favoured epcoritamab plus R (85·5% vs 40·2%). Grade 3 or higher adverse events were more frequent with epcoritamab plus R (219 [90%] of 243 participants) versus R (161 [68%] of 238 participants). Cytokine release syndrome was low grade with epcoritamab plus R (grade 1 in 28 [21%] participants and grade 2 in seven [5%] participants) and manageable, and all events were resolved.
> 
> INTERPRETATION: Epcoritamab plus R resulted in significantly higher response rate and longer progression-free survival versus R among participants with follicular lymphoma who had received at least one line of therapy. Epcoritamab plus R had more grade 3 or higher adverse events versus R. Adverse events were manageable and consistent with the established safety profiles of the individual components, with no new safety findings identified. These findings position epcoritamab plus R as a new standard of care for second-line or subsequent treatment of follicular lymphoma.
> 
> FUNDING: AbbVie and Genmab.

> **中文摘要：**
> 背景：对于复发或难治性滤泡性淋巴瘤，能够诱导持久缓解的无化疗方案仍存在未满足的需求。来那度胺联合利妥昔单抗（R）是该人群公认的标准治疗。EPCORE FL-1试验旨在评估epcoritamab联合R对比R在接受过至少一线化学免疫治疗后复发或难治性滤泡性淋巴瘤参与者中的疗效和安全性。
> 
> 方法：在这项多国、开放标签、3期试验中，参与者被随机分配（1:1）接受固定疗程的epcoritamab联合R或R治疗，最多12个周期。Epcoritamab在第1-3周期每周给药一次，第4-12周期每4周给药一次；来那度胺在第1-12周期（第1-21天）每日一次；利妥昔单抗在第1周期每周一次，第2-5周期每月一次。双重主要终点是由独立审查委员会评估的总缓解率和无进展生存期。此处报告的数据来自计划中的期中分析，该分析在78%的无进展生存事件发生后进行。本研究已在ClinicalTrials.gov（NCT05409066）和EudraCT（2021-000169-34）注册，目前正在进行中（已停止招募）。
> 
> 结果：在非洲、亚洲、澳大利亚、欧洲、北美和南美30个国家的189个学术和非学术中心筛选了668名参与者，最终共有488名参与者被随机分配，其中243名接受epcoritamab联合R治疗，245名接受R治疗。试验达到了其双重主要终点，显示epcoritamab联合R在总缓解率和无进展生存期方面优于R。中位随访14.8个月（IQR 11.4-19.0）后，epcoritamab联合R组的总缓解率为95%（95% CI 92-97），而R组为79%（74-84；p<0.0001）。Epcoritamab联合R组的无进展生存期长于R组（风险比 0.21 [95% CI 0.14-0.31]，p<0.0001）；估计的16个月无进展生存率支持epcoritamab联合R组（85.5% vs 40.2%）。Epcoritamab联合R组3级或以上不良事件发生率更高（243名参与者中有219名[90%]），而R组为（238名参与者中有161名[68%]）。Epcoritamab联合R组的细胞因子释放综合征均为低级别（1级28名[21%]参与者，2级7名[5%]参与者），可管理，且所有事件均已缓解。
> 
> 解读：在接受过至少一线治疗的滤泡性淋巴瘤参与者中，与R相比，epcoritamab联合R带来了显著更高的缓解率和更长的无进展生存期。与R相比，epcoritamab联合R的3级或以上不良事件更多。不良事件可管理，与各组分已知的安全性特征一致，未发现新的安全性问题。这些研究结果确立了epcoritamab联合R作为滤泡性淋巴瘤二线或后续治疗的新标准。
> 
> 资助：AbbVie和Genmab。

### 第二部分 AI 大师评价

本研究旨在评估在来那度胺+利妥昔单抗（R）标准方案基础上，加入双特异性抗体epcoritamab（E+R）对复发/难治性滤泡性淋巴瘤的疗效与安全性。这是一项全球多中心、随机、开放标签的3期试验，设计严谨，采用独立审查委员会评估的双重主要终点。结果显示，E+R方案在总缓解率和无进展生存期方面均显著优于R方案，疗效提升显著（ORR 95% vs 79%，HR 0.21），确立了其作为二线及以上治疗新标准的潜力。主要局限性在于随访时间尚短（中位14.8个月），长期疗效与安全性（如免疫相关不良事件）仍需更长时间观察；此外，虽然不良事件可控且与已知特征一致，但E+R组3级以上不良事件发生率更高（90% vs 68%），提示临床应用中需加强监测与管理。

---

## 16. 他法西他单抗、来那度胺和利妥昔单抗治疗复发或难治性滤泡性淋巴瘤（inMIND）：一项全球性、3期、随机对照试验。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360064)
**期刊：** Lancet (London, England)
**PMID：** 41360064
**DOI：** 10.1016/S0140-6736(25)01778-7

### 第一部分 原文与翻译

**英文原标题：** Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.

> **英文摘要：**
> BACKGROUND: Follicular lymphoma is characterised by episodes of remission and relapse, with patients requiring multiple lines of therapy. Lenalidomide plus rituximab is a commonly used immunotherapy combination in patients with relapsed or refractory follicular lymphoma. We aimed to assess the efficacy and safety of adding tafasitamab, a CD19-targeted Fc-enhanced monoclonal antibody, to lenalidomide and rituximab in this setting. METHODS: This phase 3, double-blind, randomised, placebo-controlled trial (inMIND) was done in 210 centres (including community-based haematology clinics, major hospitals, and academic institutions) in North America, Europe, and the Asia-Pacific region. Adults with relapsed or refractory follicular lymphoma, who had received at least one previous line of systemic therapy, were eligible for enrolment and randomly assigned (1:1) to receive treatment with up to 12 cycles (28-day cycle length) of tafasitamab (12 mg/kg by intravenous infusion on days 1, 8, 15, and 22 of cycles 1-3 and days 1 and 15 of cycles 4-12) or placebo, both with lenalidomide (20 mg/day orally on days 1-21 of cycles 1-12) and rituximab (375 mg/m by intravenous infusion on days 1, 8, 15, and 22 of cycle 1 and day 1 of cycles 2-5). Treatment assignment was achieved via an interactive voice or web response system; patients, investigators, and the funder were masked until the primary analysis. Study endpoints were investigator assessed unless otherwise specified. The primary endpoint was progression-free survival in the intention-to-treat population of all randomised patients; safety was assessed in all randomised patients who received at least one dose of study drug. The trial is registered with ClinicalTrials.gov (NCT04680052) and EUDRA-CT (2020-004407-13) and is active but no longer enrolling. FINDINGS: Between April 16, 2021, and Aug 10, 2023, a total of 817 patients were assessed for eligibility; 548 patients with relapsed or refractory follicular lymphoma were enrolled and randomly assigned to treatment with either tafasitamab (n=273) or placebo (n=275). 299 (55%) of all randomised patients were male and 249 (45%) were female. The addition of tafasitamab to lenalidomide and rituximab resulted in significantly lower risk of progression, relapse, or death versus placebo (median progression-free survival by investigator 22·4 months [95% CI 19·2 to not evaluable] in the tafasitamab group vs 13·9 months [11·5-16·4] in the placebo group; hazard ratio 0·43 [95% CI 0·32-0·58]; p<0·0001) in the planned primary analysis. Improvement in progression-free survival was confirmed by independent review committee. Adverse events were reported in 272 (99%) of 274 patients in the tafasitamab group and 270 (99%) of 272 patients in the placebo group. Most common adverse events occurring in either the tafasitamab group or placebo group were neutropenia (133 [49%] vs 123 [45%]) and diarrhoea (103 [38%] vs 77 [28%]). There were no deaths due to treatment-related adverse events in the tafasitamab group; two (1%) patients had fatal adverse events related to treatment in the placebo group. INTERPRETATION: The addition of tafasitamab to lenalidomide and rituximab resulted in a statistically significant and clinically meaningful improvement in progression-free survival, with an acceptable safety profile in patients with relapsed or refractory follicular lymphoma. This combination represents a potential new standard-of-care treatment. FUNDING: Incyte.

> **中文摘要：**
> 背景：滤泡性淋巴瘤的特点是缓解与复发交替发生，患者需要接受多线治疗。来那度胺联合利妥昔单抗是复发或难治性滤泡性淋巴瘤患者常用的免疫治疗组合。本研究旨在评估在此方案基础上添加他法西他单抗（一种靶向CD19的Fc增强型单克隆抗体）的疗效和安全性。方法：这项3期、双盲、随机、安慰剂对照试验（inMIND）在北美、欧洲和亚太地区的210个中心（包括社区血液病诊所、大型医院和学术机构）进行。既往至少接受过一线全身治疗的复发或难治性滤泡性淋巴瘤成人患者符合入组条件，并按1:1比例随机分配接受最多12个周期（每个周期28天）的他法西他单抗（第1-3周期第1、8、15、22天静脉输注12 mg/kg，第4-12周期第1、15天给药）或安慰剂治疗，两组均联合使用来那度胺（第1-12周期第1-21天口服20 mg/天）和利妥昔单抗（第1周期第1、8、15、22天及第2-5周期第1天静脉输注375 mg/m²）。治疗分配通过交互式语音或网络应答系统实现；患者、研究者和资助方在主要分析前均处于盲态。除非另有说明，研究终点由研究者评估。主要终点是所有随机患者的意向治疗人群的无进展生存期；安全性在所有随机并接受至少一剂研究药物的患者中进行评估。该试验已在ClinicalTrials.gov（NCT04680052）和EUDRA-CT（2020-004407-13）注册，目前正在进行中但已停止招募。结果：2021年4月16日至2023年8月10日期间，共评估了817名患者的资格；548名复发或难治性滤泡性淋巴瘤患者入组并随机分配接受他法西他单抗（n=273）或安慰剂（n=275）治疗。所有随机患者中，299名（55%）为男性，249名（45%）为女性。在计划的主要分析中，与安慰剂相比，在他法西他单抗组中添加他法西他单抗显著降低了疾病进展、复发或死亡的风险（研究者评估的中位无进展生存期：他法西他单抗组为22.4个月[95% CI 19.2至不可评估]，安慰剂组为13.9个月[11.5-16.4]；风险比为0.43 [95% CI 0.32-0.58]；p<0.0001）。无进展生存期的改善得到了独立审查委员会的确认。他法西他单抗组274名患者中有272名（99%）、安慰剂组272名患者中有270名（99%）报告了不良事件。他法西他单抗组或安慰剂组中最常见的不良事件是中性粒细胞减少症（133例 [49%] vs 123例 [45%]）和腹泻（103例 [38%] vs 77例 [28%]）。他法西他单抗组中无治疗相关不良事件导致的死亡；安慰剂组中有两名（1%）患者发生了与治疗相关的致命不良事件。解读：在来那度胺和利妥昔单抗基础上添加他法西他单抗，在复发或难治性滤泡性淋巴瘤患者中带来了具有统计学显著性和临床意义的无进展生存期改善，且安全性可接受。该联合方案代表了一种潜在的新标准治疗方案。资助方：Incyte。

### 第二部分 AI 大师评价

本研究旨在评估在来那度胺+利妥昔单抗（R²）标准方案基础上，联合CD19靶向Fc增强型单抗他法西他单抗（T）治疗复发/难治性滤泡性淋巴瘤（R/R FL）的疗效与安全性。通过一项全球多中心、双盲、安慰剂对照的3期试验（inMIND），研究证实三联方案（T+R²）相比R²方案能显著延长中位无进展生存期（22.4个月 vs 13.9个月，HR=0.43），且安全性可控，主要不良事件为血液学毒性和腹泻。其创新性在于首次在大型3期试验中验证了CD19靶向抗体联合免疫调节剂和抗CD20抗体在R/R FL中的协同增效作用，有望成为新的标准治疗选择；局限性在于长期总生存数据和后续治疗影响尚待进一步随访确认。

---

## 17. 复发或难治性滤泡性淋巴瘤的新标准。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360063)
**期刊：** Lancet (London, England)
**PMID：** 41360063
**DOI：** 10.1016/S0140-6736(25)01965-8

### 第一部分 原文与翻译

**英文原标题：** A new standard for relapsed or refractory follicular lymphoma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文标题明确指向为复发或难治性滤泡性淋巴瘤确立新的治疗标准，暗示可能是一项重要的临床试验或系统性综述。鉴于摘要不可用，推测其核心目的可能是评估一种新疗法或治疗策略的疗效与安全性。其潜在创新性在于可能为该临床困境提供了更优的解决方案，但缺乏摘要信息也构成了主要局限性，无法评估其具体研究方法、关键发现及证据强度。

---

速递结束，祝您工作愉快！